MyeloMATCH: The New Front in the Battle Against Leukemia

In this episode of the Bench to Bedside Podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses exciting advancements in the treatment of acute myeloid leukemia (AML) with Dr. Tara Lin, director of the adult leukemia program at KU Cancer Center and site principal investigator for myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice), a precision-medicine initiative sponsored by the National Cancer Institute (NCI). MyeloMATCH is an “umbrella trial,” a group of clinical substudies for people with acute myeloid leukemia or myelodysplastic syndrome. In this conversation Dr. Lin explains the challenges of AML, as well as the innovative aspects of the myeloMATCH trial, such as rapid diagnostic testing and specialized clinical trial options based on genetic and molecular features.

Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

Links from this Episode:

• Learn more about the myeloMATCH trial
• View the myleoMATCH trial on the NCI’s clinical trials database
• Learn more about AML
• Read about clinical trials at KU Cancer Center
• Learn more about Dr. Tara Lin